Xueyan Liang - Concepedia

Author

Xueyan Liang

The People's Hospital of Guangxi Zhuang Autonomous Region ORCID

Also Known As

X Liang, X. Liang, Xueyan Liang

Publications

516

Citations

H-Index

Concepts

All Affiliations

The People's Hospital of Guangxi Zhuang Autonomous Region Guangxi Medical University First Affiliated Hospital of GuangXi Medical University

About

Xueyan Liang is an author at The People's Hospital of Guangxi Zhuang Autonomous Region specializing in engineering, biochemical engineering, and biomass conversion.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	1	1	19
2	Biochemical Engineering	1	1	19
3	Biomass Conversion	1	1	19

Xueyan Liang

Publications

230

Citations

H-Index

Page 1

	Year	Citations
2D Film‐Like Magnetic SERS Tag with Enhanced Capture and Detection Abilities for Immunochromatographic Diagnosis of Multiple Bacteria Jiaxuan Li, Wanzhu Shen, Xueyan Liang, Small	2024	71
<i>Panax notoginseng saponins</i> mitigate cisplatin induced nephrotoxicity by inducing mitophagy via HIF-1α Xueyan Liang, Yufang Yang, Zhenguang Huang, Oncotarget	2017	32
<i>Panax notoginseng</i> saponins ameliorate cisplatin‐induced mitochondrial injury via the HIF‐1α/mitochondria/ROS pathway Qingqing Li, Xueyan Liang, Yufang Yang, FEBS Open Bio	2019	32
Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis Yan Li, Xueyan Liang, Huijuan Li, Cancer	2022	28
Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis Yan Li, Xueyan Liang, Huijuan Li, Frontiers in Pharmacology	2022	21
Effect of ball milling on enzymatic sugar production from fractionated corn stover Kaili Ding, Hao Lin, Luoyang Liu, Industrial Crops and Products Biomass ConversionEngineeringBiochemical EngineeringBall MillingEnzymatic Sugar Production	2023	19
Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer Xueyan Liang, Xiaoyu Chen, Huijuan Li, Frontiers in Public Health	2023	15
Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer Demin Shi, Yan Li, Xueyan Liang, Frontiers in Oncology	2023	12

Page 1